VEGFA and neoplasm: Followed by intravenous administration, G-CD-PEG-AA/vascular endothelial growth factor (VEGF) siRNA exhibited a threefold reduction in tumor volume as compared to PBS while non-targeted carriers were unable to demonstrate a noticeable anti-tumor effect [90].